keyword
https://read.qxmd.com/read/38639764/-allergen-immunotherapy-for-rare-allergens
#1
REVIEW
Guido Mühlmeier, Marie-Luise Polk, Matthias Tisch, Mandy Cuevas
Among allergies to aeroallergens, approximately 20% are allotted to the so-called rare allergens. These include ash pollen, weed pollen, storage mites, molds, and animal allergens. The prevalences of allergies to these allergens are lower, but affected patients also suffer considerably from their "rare" allergy. Hence, these allergies should neither be overseen nor completely forgotten in daily practice. Especially mold, mite, and animal allergens often induce asthma, so that the significance of allergen-specific immunotherapy (AIT) should not be neglected in causal therapy...
April 19, 2024: HNO
https://read.qxmd.com/read/38169056/peripheral-blood-mononuclear-cell-transcriptome-profile-in-a-clinical-trial-with-subcutaneous-grass-pollen-allergoid-immunotherapy
#2
JOURNAL ARTICLE
Sviatlana Starchenka, Kemi Oluwayi, Matthew Heath, Oliver Armfield, Mohamed Shamji, Janice Layhadi, Katarzyna Lis, Lisa Cadavez, Olesya Rusyn, Murray Skinner, Pieter-Jan De Kam
INTRODUCTION: Allergen-specific immunotherapy (AIT) is the only disease-modifying treatment in allergic airway diseases. Underlying immunological mechanisms and candidate biomarkers, which may be translated into predictive/surrogate measures of clinical efficacy, remain an active area of research. The aim of this study was to evaluate Pollinex Quattro (PQ) Grass AIT induced immunomodulatory mechanisms, based on transcriptome profiling of peripheral blood mononuclear cells. METHODS: 119 subjects with grass pollen induced seasonal allergic rhinitis (SAR) were randomized in a 2:2:1:1 ratio to receive a cumulative dose of PQ Grass as a conventional or extended pre-seasonal regimen, placebo, or placebo with MicroCrystalline Tyrosine...
January 2, 2024: Clinical and Experimental Allergy
https://read.qxmd.com/read/38146840/long-term-effects-of-pollen-allergoid-tyrosine-adsorbed-subcutaneous-immunotherapy-on-allergic-rhinitis-and-asthma
#3
JOURNAL ARTICLE
Christian Vogelberg, Ludger Klimek, Silvia Kruppert, Sven Becker
BACKGROUND: Allergen immunotherapy (AIT) may have a long-term disease-modifying effect. The aim of this study was to demonstrate the long-term effects of pollen allergoid tyrosine-adsorbed subcutaneous AIT on allergic rhinitis (AR) and asthma (AA) in clinical practice. METHODS: This retrospective study, funded by an AIT manufacturer, analysed the impact of AIT on AR progression and onset of need for AA medication, using a German database covering ~35% of national prescriptions during 2008-2020...
December 26, 2023: Clinical and Experimental Allergy
https://read.qxmd.com/read/38034768/t-cell-subset-changes-during-the-first-year-of-pre-seasonal-allergoid-allergen-specific-immunotherapy
#4
JOURNAL ARTICLE
Manuel Reithofer, Simone Lisa Boell, Claudia Kitzmueller, Fritz Horak, Barbara Bohle, Beatrice Jahn-Schmid
Allergen-specific immunotherapy (AIT) is the only treatment for type I allergy, which achieves long-lasting effects. Repeated subcutaneous applications of allergen extracts cause a protective antibody response and an immune deviation of T cells. In AIT with allergoids, chemically modified allergen extracts are injected. During a so-called special pre-seasonal application scheme, after the initial phase of applying increased doses of allergoids is followed by natural allergen exposure as a maintenance phase...
November 2023: Heliyon
https://read.qxmd.com/read/38018469/safety-of-subcutaneous-and-sublingual-immunotherapy-with-allergoids-in-children-a-real-life-pharmacovigilance-study
#5
JOURNAL ARTICLE
Franco Frati, Noemi De Beni, Laura Marastoni, Enrico Compalati, Giorgio Ciprandi
Aims: Allergen-specific immunotherapy uses a sublingual (sublingual immunotherapy [SLIT]) or subcutaneous (subcutaneous immunotherapy [SCIT]) route. This pharmacovigilance study aimed to determine the number and type of adverse drug reactions (ADRs) for SLIT and SCIT using carbamylated monomeric allergoids (CMAs) in children. Materials & methods: This pharmacovigilance study analyzed real-world post-marketing reports collected from a safety database of Lais sublingual tablets and injective Lais-in, containing CMAs for over 10 years...
November 29, 2023: Immunotherapy
https://read.qxmd.com/read/37822222/a-randomized-double-blind-placebo-controlled-trial-with-mannan-conjugated-birch-pollen-allergoids
#6
JOURNAL ARTICLE
Ralph Mösges, Christoph Zeyen, Esther Raskopf, Cengizhan Acikel, Hacer Sahin, Silke Allekotte, Mandy Cuevas, Mohamed H Shamji, José Luis Subiza, Miguel Casanovas
BACKGROUND: There is still great need to develop new strategies to improve the efficacy of allergen immunotherapies with optimal safety standards for patients. A new promising approach is to couple allergoids to mannan. The objective of this phase IIa/IIb study was to identify the optimal dose of mannan-conjugated birch pollen allergoids for the short-course treatment of birch pollen-induced allergic rhinoconjunctivitis. METHODS: For this prospective, randomized, double-blind, placebo-controlled, dose-finding study, 246 birch pollen-allergic adults received 0...
October 12, 2023: Allergy
https://read.qxmd.com/read/37445362/subcutaneous-immunotherapy-scit-with-the-new-polymerized-molecular-allergoid-alt-a1-a-pilot-study-in-children-with-allergic-rhinitis-sensitized-to-alternaria-alternata
#7
JOURNAL ARTICLE
Giulia Brindisi, Alessandra Gori, Caterina Anania, Ivana Martinelli, Martina Capponi, Giovanna De Castro, Anna Maria Zicari
BACKGROUND: We followed the effects of a new SCIT with a chemically polymerized allergen Alt a1, evaluating the trend of clinical and functional parameters in an observational-prospective study. METHODS: 42 children with AR and intermittent asthma sensitized to A.A.: 17 patients started SCIT (Modigoid® ), and 25 continued symptomatic therapy. At the initial visit (T0), all patients performed total IgE (tIgE) and specific IgE (sIgE) for Alt a1, nasal nitric oxide (nFeNo), nasal cytology, anterior active rhinomanometry (AAR) and spirometry...
June 27, 2023: Journal of Clinical Medicine
https://read.qxmd.com/read/37387214/is-there-a-rationale-for-supplementing-with-vitamin-d-patients-under-treatment-with-allergen-immunotherapy
#8
JOURNAL ARTICLE
Mario Di Gioacchino, Claudia Petrarca, Loredana Della Valle, Rocco Mangifesta, Francesca Santilli
Vitamin D (VD) has been shown to exert immunomodulatory activities, especially in promoting immune tolerance. For these properties VD has been proposed in the therapy of immunological conditions in which the loss of tolerance is the key pathogenetic aspect of the disease, such as allergies. Despite these properties available literature suggests VD is not useful in treating or preventing allergic diseases and whether low serum VD levels favor allergic sensitization and severity is debated. The level of VD is one of the many conditions that can influence allergic sensitization and therefore only a multivariate analysis on a numerically adequate cohort of patients, that considers all the factors that can favor allergy, would be able to assign the weight of each variable and determine the extent to which VD inhibits allergic sensitization and march...
December 2023: Annals of Medicine
https://read.qxmd.com/read/37371795/vitamin-d-role-in-childhood-mite-allergy-and-allergen-immunotherapy-ait
#9
JOURNAL ARTICLE
Claudia Petrarca, Davide Viola
The post hoc analysis presented here aimed to address the influence of endogenous vitamin D in the immunological mechanism underlying effective mite allergoid immunotherapy (AIT). Previously, we have shown that in allergic children, after 12 months of this immunoactive treatment, functionally potentiated memory regulatory T cells are identified. Indeed, AIT is the only known treatment that is able to reshape the detrimental immune response against the allergen into a non-noxious one. Besides, VD is widely considered an immunoregulatory molecule that is endogenously produced and exogenously provided by foods and supplements that might interact with the AIT mechanism, thus affecting its outcome...
June 13, 2023: Biomedicines
https://read.qxmd.com/read/37122076/allergen-immunotherapy-progress-and-future-outlook
#10
REVIEW
Lara Šošić, Marta Paolucci, Stephan Flory, Fadi Jebbawi, Thomas M Kündig, Pål Johansen
INTRODUCTION: Allergy, the immunological hypersensitivity to innocuous environmental compounds, is a global health problem. The disease triggers, allergens, are mostly proteins contained in various natural sources such as plant pollen, animal dander, dust mites, foods, fungi, and insect venoms. Allergies can manifest with a wide range of symptoms in various organs and be anything from just tedious to life-threatening. A majority of all allergy patients are self-treated with symptom-relieving medicines, while allergen immunotherapy (AIT) is the only causative treatment option...
2023: Expert Review of Clinical Immunology
https://read.qxmd.com/read/36872361/evolution-of-immunotherapy-against-pollen-allergy
#11
JOURNAL ARTICLE
Mistrello Gianni
Allergic diseases have increased worldwide during the last century and are a major disease burden globally. Several substances can induce allergic sensitization and elicit allergic symptoms in sensitized individuals. Pollen grains are one of the main causes of allergic rhinitis and asthma, and the prevalence of different pollen species depends on the climate, geographical regions, flora, and season. In addition to avoiding exposure to pollens, anti-allergic drugs are commonly used to mitigate the symptoms of allergies...
March 3, 2023: Current Protein & Peptide Science
https://read.qxmd.com/read/36720753/c-type-lectin-receptor-mediated-modulation-of-t2-immune-responses-to-allergens
#12
REVIEW
Alba Angelina, Leticia Martín-Cruz, Andrés de la Rocha-Muñoz, Begoña Lavín-Plaza, Oscar Palomares
PURPOSE OF REVIEW: Allergic diseases represent a major health problem of increasing prevalence worldwide. In allergy, dendritic cells (DCs) contribute to both the pathophysiology and the induction of healthy immune responses to the allergens. Different studies have reported that some common allergens contain glycans in their structure. C-type lectin receptors (CLRs) expressed by DCs recognize carbohydrate structures and are crucial in allergen uptake, presentation, and polarization of T cell responses...
February 1, 2023: Current Allergy and Asthma Reports
https://read.qxmd.com/read/36649758/single-cell-rna-seq-identifies-precise-tolerogenic-cellular-and-molecular-pathways-induced-by-depigmented-polymerized-grass-pollen-allergen-extract
#13
JOURNAL ARTICLE
Janice A Layhadi, Raquel Moya, Tiak Ju Tan, Madison M Lenormand, Hanisah Sharif, Rebecca V Parkin, Gemma Vila-Nadal, Oleksandra Fedina, Rongfei Zhu, Wannada Laisuan, Stephen R Durham, Jerónimo Carnés, Mohamed H Shamji
BACKGROUND: Immunological mechanism of action of allergoids remains poorly understood. Previous models of allergenicity and immunogenicity have yielded sub-optimal knowledge of these immunotherapeutic vaccine products. Novel single-cell RNA-seq technology offers a bridge to this gap in knowledge. OBJECTIVE: To identify the underpinning tolerogenic molecular and cellular mechanisms of depigmented-polymerized Phleum pratense extract. METHODS: The molecular mechanisms underlying native Phleum pratense (Phl p), depigmented Phl p (DPG-Phl p), and depigmented-polymerized (DPG-POL-Phl p) allergoid were investigated using scRNA-seq...
January 14, 2023: Journal of Allergy and Clinical Immunology
https://read.qxmd.com/read/36556000/real-life-effectiveness-of-subcutaneous-immune-therapy-with-carbamylated-monomeric-allergoids-on-mite-grass-and-pellitory-respiratory-allergy-a-retrospective-study
#14
JOURNAL ARTICLE
Mario Di Gioacchino, Loredana Della Valle, Rocco Mangifesta, Arianna Lumaca, Francesco Cipollone, Franco Frati, Enrico Compalati, Eralda Lekli, Etleva Qirco Loloci, Francesca Santilli
BACKGROUND: real-life studies are encouraged to evaluate the effectiveness and safety of allergen immunotherapy (AIT). In this context, a retrospective cohort study was conducted to assess the effectiveness and safety of carbamylated monomeric allergoid subcutaneous immunotherapy (MA-SCIT), along with patient satisfaction. METHODS: a total of 291 patients with rhinoconjunctivitis with or without asthma with inhalant (house dust mite, grass, and pellitory) allergies were enrolled in this study...
December 12, 2022: Journal of Clinical Medicine
https://read.qxmd.com/read/36494877/from-trained-immunity-in-allergy-to-trained-immunity-based-allergen-vaccines
#15
REVIEW
Leticia Martín-Cruz, Carmen Sevilla-Ortega, Alba Angelina, Jorge Domínguez-Andrés, Mihai G Netea, José Luis Subiza, Oscar Palomares
Innate immune cells experience long lasting metabolic and epigenetic changes after an encounter with specific stimuli. This facilitates enhanced immune responses upon secondary exposition to both the same and unrelated pathogens, a process termed trained immunity. Trained immunity-based vaccines (TIbV) are vaccines able to induce innate immune memory, thus conferring heterologous protection against a broad range of pathogens. While trained immunity has been well documented in the context of infections and multiple immune-mediated diseases, the role of innate immune memory and its contribution to the initiation and maintenance of chronic allergic diseases remains poorly understood...
December 9, 2022: Clinical and Experimental Allergy
https://read.qxmd.com/read/36457720/111-years-of-allergen-immunotherapy-a-long-and-successful-history-of-the-only-available-disease-modifier-in-allergic-diseases
#16
REVIEW
Jan Gutermuth, Martine Grosber, Oliver Pfaar, Karl Christian Bergmann, Johannes Ring
The great milestones in medicine almost always have their precursors, which help the great event to break through. So it was with allergen-specific immunotherapy (AIT) and the great work of Noon and Freeman and their world-renowned publication in 1911. In this article, we want to outline AIT's long journey, from early attempts to achieve tolerance to allergens in the environment. Many very different methods were used; from homeopathy to the use of recombinant allergens. Initially, the allergen extracts were given only subcutaneously, but then also through other routes, such as nasal, rectal, intradermal, epicutaneous, in lymph nodes, or oral...
2022: Allergologie Select
https://read.qxmd.com/read/36397261/new-approaches-to-immunotherapy-in-house-dust-mite-allergy
#17
JOURNAL ARTICLE
In Sik Kim
Allergen immunotherapy (AIT) has developed over the last few decades and has emerged as a promising treatment. House dust mite is a target allergen in AIT, and various modified house dust mite allergens have been improved for their efficacy. Moreover, clinical trials have proved their significantly therapeutic effects in allergy. This article review focuses on house dust mite allergens developed for AIT efficacy, and determines that their action mechanisms are strongly based on immune tolerance. Treatments for house dust mite allergens have been optimized by modification or/and addition of adjuvants, and clinically evaluated by subcutaneous and sublingual administration...
October 25, 2022: Clinical and experimental pediatrics
https://read.qxmd.com/read/36059475/modulation-of-dendritic-cell-metabolism-by-an-mpla-adjuvanted-allergen-product-for-specific-immunotherapy
#18
JOURNAL ARTICLE
Jennifer Zimmermann, Alexandra Goretzki, Clara Meier, Sonja Wolfheimer, Yen-Ju Lin, Hannah Rainer, Maren Krause, Saskia Wedel, Gerd Spies, Frank Führer, Stefan Vieths, Stephan Scheurer, Stefan Schülke
Background: Recently, bacterial components were shown to enhance immune responses by shifting immune cell metabolism towards glycolysis and lactic acid production, also known as the Warburg Effect. Currently, the effect of allergen products for immunotherapy (AIT) and commercial vaccines on immune cell metabolism is mostly unknown. Objective: To investigate the effect of AIT products (adjuvanted with either MPLA or Alum) on myeloid dendritic cell (mDC) metabolism and activation...
2022: Frontiers in Immunology
https://read.qxmd.com/read/36047760/clinical-evaluation-of-subcutaneous-immunotherapy-with-a-polymerized-molecular-allergoid-of-alt-a-1-in-patients-with-allergic-rhinoconjunctivitis-and-or-allergic-asthma-caused-by-the-mould-alternaria-alternata
#19
JOURNAL ARTICLE
Á Ferrer
This is a retrospective analysis of the clinical evolution of 14 patients diagnosed with allergic rhinoconjunctivitis (AR) and/or allergic asthma (AA) caused by Alternaria alternata , who were attended by the allergology service of Vega Baja Hospital of Orihuela (Alicante, Spain). The purpose was to assess the clinical impact and safety of 1-year of subcutaneous immunotherapy with a polymerized molecular allergoid of Alt a 1. Impact of the treatment on allergic diseases (mean number AR/AA episodes and ARIA/GINA classifications), changes in symptoms and prescribed medication, change in the global subjective clinical status of patients and satisfaction with the treatment were also evaluated...
September 1, 2022: European Annals of Allergy and Clinical Immunology
https://read.qxmd.com/read/36046924/safety-of-subcutaneous-immunotherapy-with-carbamylated-allergoids-based-on-data-from-a-pharmacovigilance-database
#20
JOURNAL ARTICLE
Frati Franco, Incorvaia Cristoforo, Silvestri Francesca, Pisani Arianna, Marastoni Laura, Cavalieri Carlo, Masieri Simonetta, Compalati Enrico
Aims: Allergen immunotherapy aims to induce tolerance, which persists after its discontinuation, to targeted allergens. However, concern exists regarding the use of subcutaneous immunotherapy with whole extracts due to frequently reported events of anaphylactic reactions. Materials & methods: In this pharmacovigilance study, the authors assessed the safety of subcutaneous immunotherapy with the monomeric allergoid Lais-in using a database of adverse reactions documented in real-world postmarketing reports from 2010 to 2020...
August 31, 2022: Immunotherapy
keyword
keyword
109765
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.